Recruiting studies: Dll3 Expressing Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1/Phase 2 · 15 location(s) · Phanes Therapeutics · NCT05652686 DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
NA · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT07458906 Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496 A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Phase 1/Phase 2 · 13 location(s) · IDEAYA Biosciences · NCT07174583 Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
Phase 2 · 5 location(s) · Jonsson Comprehensive Cancer Center · NCT06788938 Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Sol
Phase 1/Phase 2 · 5 location(s) · Molecular Partners AG · NCT07278479 A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours T
Phase 1 · 12 location(s) · Boehringer Ingelheim · NCT04429087 Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Phase 1 · 7 location(s) · Novartis Pharmaceuticals · NCT07006727

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.